Innoviva EBITDA 2010-2024 | INVA
Innoviva ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Innoviva Annual EBITDA
(Millions of US $) |
| 2023 |
$152 |
| 2022 |
$495 |
| 2021 |
$398 |
| 2020 |
$343 |
| 2019 |
$265 |
| 2018 |
$259 |
| 2017 |
$202 |
| 2016 |
$126 |
| 2015 |
$49 |
| 2014 |
$-18 |
| 2013 |
$-21 |
| 2012 |
$-18 |
| 2011 |
$-102 |
| 2010 |
$-72 |
| 2009 |
$-76 |
Innoviva Quarterly EBITDA
(Millions of US $) |
| 2024-09-30 |
$54 |
| 2024-06-30 |
$65 |
| 2024-03-31 |
$36 |
| 2023-12-31 |
$48 |
| 2023-09-30 |
$28 |
| 2023-06-30 |
$37 |
| 2023-03-31 |
$38 |
| 2022-12-31 |
$30 |
| 2022-09-30 |
$297 |
| 2022-06-30 |
$87 |
| 2022-03-31 |
$82 |
| 2021-12-31 |
$110 |
| 2021-09-30 |
$100 |
| 2021-06-30 |
$102 |
| 2021-03-31 |
$85 |
| 2020-12-31 |
$90 |
| 2020-09-30 |
$90 |
| 2020-06-30 |
$81 |
| 2020-03-31 |
$81 |
| 2019-12-31 |
$79 |
| 2019-09-30 |
$65 |
| 2019-06-30 |
$64 |
| 2019-03-31 |
$57 |
| 2018-12-31 |
$82 |
| 2018-09-30 |
$63 |
| 2018-06-30 |
$68 |
| 2018-03-31 |
$46 |
| 2017-12-31 |
$72 |
| 2017-09-30 |
$45 |
| 2017-06-30 |
$52 |
| 2017-03-31 |
$33 |
| 2016-12-31 |
$42 |
| 2016-09-30 |
$32 |
| 2016-06-30 |
$30 |
| 2016-03-31 |
$22 |
| 2015-12-31 |
$21 |
| 2015-09-30 |
$13 |
| 2015-06-30 |
$10 |
| 2015-03-31 |
$5 |
| 2014-12-31 |
$5 |
| 2014-09-30 |
$-5 |
| 2014-06-30 |
$-6 |
| 2014-03-31 |
$-11 |
| 2013-12-31 |
$22 |
| 2013-09-30 |
$-6 |
| 2013-06-30 |
$-5 |
| 2013-03-31 |
$-31 |
| 2012-12-31 |
$-28 |
| 2012-09-30 |
$-31 |
| 2012-06-30 |
$-34 |
| 2012-03-31 |
$88 |
| 2011-12-31 |
$-33 |
| 2011-09-30 |
$-27 |
| 2011-06-30 |
$-22 |
| 2011-03-31 |
$-20 |
| 2010-12-31 |
$-16 |
| 2010-09-30 |
$-18 |
| 2010-06-30 |
$-18 |
| 2010-03-31 |
$-20 |
| 2009-12-31 |
$-19 |
| 2009-09-30 |
$-20 |
| 2009-06-30 |
$-20 |
| 2009-03-31 |
$-17 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.122B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
